Results 111 to 120 of about 2,854 (152)

Ezetimibe and the risk of new-onset type 2 diabetes: a systematic review and meta-analysis. [PDF]

Ann Med
Albawa'neh AS, Alqasrawi MN, Al-Mahayri ZN, Albawaana A, Ahmed G, Al-Rifai RH, Ali BR.   +6 more
europepmc   +1 more source

Effect of evolocumab on the gut microbiota in patients with acute myocardial infarction. [PDF]

J Med Microbiol
Zou J, Peng Y, Cai H, Zhong Q, Zhu N, Gu W, Yang F, Shi T, Yang S, Chen L.   +9 more
europepmc   +1 more source

Achieving LDL-Cholesterol Goals: Can Implementation Science Save Us? [PDF]

Arq Bras Cardiol
Cesena FY.
europepmc   +1 more source

Efficacy and safety of PCSK-9 inhibitors in patients with acute coronary syndrome: a systematic review and network meta-analysis. [PDF]

BMC Cardiovasc Disord
Kao G, Chen C, Zhang Y, Xu Y, Xu G.
europepmc   +1 more source

Treatment with PCSK9 monoclonal antibodies is associated with discontinuation of oral lipid lowering therapy. [PDF]

Eur Heart J Qual Care Clin Outcomes
Engebretsen I, Ødegaard KM, Halvorsen S, Bugge C, Kristiansen IS, Støvring H, Munkhaugen J.   +6 more
europepmc   +1 more source

Implementation of a nonstatin prior authorization checklist for patients with hypercholesterolemia: In 2 community health care systems. [PDF]

J Manag Care Spec Pharm
McCormick D, Taub PR, Carter J, Moreo K, Heggen CL.   +4 more
europepmc   +1 more source

High-Intensity Statin versus Upfront Equivalent-Dose Combination of Moderate-Intensity Statin with Ezetimibe Following Acute Myocardial Infarction (ROSUZET-AMI): protocol of a multicentre, open-label, randomised non-inferiority trial. [PDF]

BMJ Open
Choo EH, Kim CJ, Hwang BH, Lee KY, Oh GC, Lim S, Choi IJ, Kim DB, Kwon OS, Lee S, Choi Y, Park CS, Park MW, Kim HY, Lee HC, Kang TS, Sung JK, Woo SI, Park HS, Yun KH, Chang K, ROSUZET-AMI investigator.   +21 more
europepmc   +1 more source

[Arteriosclerosis with special reference to anticholesteremic agents].

Naika. Internal medicine, 1970
M, Murakami, H, Sekimoto, I, Nakada, T, Takegoshi, N, Iwaki   +4 more
openaire   +2 more sources

[Clinical evaluation of anticholesteremic agents].

Naika. Internal medicine, 1968
T, Kimura, H, Kudo
openaire   +2 more sources

[Contribution to anticholesteremic agents?].

Ugeskrift for laeger, 1998
P, Astrup, F, Gyntelberg
openaire   +2 more sources